Agreements reached under this partnership
Business partnership (exclusive distribution agreement in Japan)- 1
BIOLAB: Manufacturing and supply (manufacturer)
- 2
AIDEN LAB JAPAN: Coordination of import agency services, domestic regulatory approvals and official distribution
- 3
The Company: Exclusive distribution and marketing in Japan (exclusive master distributor in Japan)
- 4
Directly operated stores, wholesale and online channels
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The launch of sales under this agreement is expected to increase sales of the brand and affect profit, but these effects have not been incorporated into the full-year earnings forecast. The impact of this matter on full-year results is currently under review, and the Company will promptly disclose any impact if one arises.
| Item | Details |
|---|---|
| Name of alliance partner | 株式会社AIDEN LAB JAPAN, BIOLAB Corp.（株式会社BIOLAB） |
| Alliance partner's business activities | Coordination of the import and export of iHEAL products, domestic regulatory approvals and registrations, official distribution, marketing and brand development, Research and production of femcare lactic acid bacteria, and development of the iHEAL brand |
| Alliance partner's location | Shibuya, Tokyo, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea |
| Alliance partner's capital | ¥1 million (parent company Aidenlab: approximately ¥14 million), ¥140 million |
| Type of alliance | Business partnership (exclusive distribution agreement in Japan) |
| Details of the alliance | BIOLAB: Manufacturing and supply (manufacturer), AIDEN LAB JAPAN: Coordination of import agency services, domestic regulatory approvals and official distribution, The Company: Exclusive distribution and marketing in Japan (exclusive master distributor in Japan), Directly operated stores, wholesale and online channels |
| Contract Date | June 2026 |
| Alliance start date | Full-scale sales are scheduled to begin in the second half of the fiscal year ending January 2027. |
| Impact on Business Performance | The launch of sales under this agreement is expected to increase sales of the brand and affect profit, but these effects have not been incorporated into the full-year earnings forecast. The impact of this matter on full-year results is currently under review, and the Company will promptly disclose any impact if one arises. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.By combining iHEAL’s brand strength and patented lactic acid bacteria, which are well received in Korea, with the business foundation for women’s products that the Company has developed through its women’s footwear business, the Company aims to develop Japan’s femcare market and expand sales and contribute to profits.